The Gut Microbiota Metabolite Urolithin B Improves Cognitive Deficits by Inhibiting Cyt C-Mediated Apoptosis and Promoting the Survival of Neurons Through the PI3K Pathway in Aging Mice
Overview
Affiliations
Despite considerable advances in pharmacotherapy, more effective therapeutic interventions for aging-related neurodegenerative disorders (NDs), such as Alzheimer's disease (AD), remain limited. Urolithin B (UB), one of the major subcategories of urolithins (microbiota metabolites) found in various tissues after ellagitannin consumption, has been shown to possess antioxidant, anti-inflammatory, and antiapoptotic effects. However, the neuroprotective effect of UB on brain aging in mice and its potential mechanisms were still unknown. In the current research, we first assessed the ameliorative effects of UB on oxidative injury and apoptosis induced by HO in neuro-2a cells. Then a subcutaneous injection of D-galactose in mice for 8 weeks was used to establish the aging model to evaluate the protective effects of UB. The capacity of memory and learning, alterations of hippocampus histology and corresponding molecular mechanisms were all evaluated. The D-gal-induced accelerated aging model demonstrated that UB could significantly ameliorate deficits in learning and memory by inhibiting the accumulation of advanced glycation end products (AGEs) and elevating the expression and activity of Cu, Zn-SOD and CAT. Furthermore, UB downregulated the c-Jun N-terminal kinase (JNK) signaling pathway and prevented cytochrome c release from isolated mitochondria, thereby inhibiting neuronal apoptosis during the aging process. More importantly, UB stimulation of aging mice activated ERK and phosphoinositide 3-kinase (PI3K), leading to neuronal survival along with Akt and p44/42 mitogen-activated protein kinase (MAPK) phosphorylation and activation. In summary, UB effectively alleviated cognitive deficits and ameliorated brain aging-related conditions and could be considered a healthcare product to prevent aging-associated NDs such as AD.
From the gut to the brain: the long journey of phenolic compounds with neurocognitive effects.
Dominguez-Lopez I, Lopez-Yerena A, Vallverdu-Queralt A, Pallas M, Lamuela-Raventos R, Perez M Nutr Rev. 2024; 83(2):e533-e546.
PMID: 38687609 PMC: 11723161. DOI: 10.1093/nutrit/nuae034.
Shen C, Huang B, Charoensaensuk V, Yang L, Tsai C, Liu Y Nutrients. 2023; 15(23).
PMID: 38068712 PMC: 10708538. DOI: 10.3390/nu15234854.
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis.
Kujawa D, Laczmanski L, Budrewicz S, Pokryszko-Dragan A, Podbielska M Gut Microbes. 2023; 15(2):2274126.
PMID: 37979154 PMC: 10730225. DOI: 10.1080/19490976.2023.2274126.
Urolithins: A Prospective Alternative against Brain Aging.
An L, Lu Q, Wang K, Wang Y Nutrients. 2023; 15(18).
PMID: 37764668 PMC: 10534540. DOI: 10.3390/nu15183884.
Bioactive Compounds for Customized Brain Health: What Are We and Where Should We Be Heading?.
Begdache L, Marhaba R Int J Environ Res Public Health. 2023; 20(15).
PMID: 37569058 PMC: 10418716. DOI: 10.3390/ijerph20156518.